NYSE:NUVB
Nuvation Bio Inc.
Nuvation Bio Inc.'s revenue grew 699.0% in fiscal 2025 to $62.9M while operating margin rose to −338.7%. The diluted share count rose 27.1%.Summary generated from Nuvation Bio Inc.'s SEC filings. Latest annual report filed Mar 2, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$62.9M
Revenue growth+699.0%
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating margin−338.7%
Net margin−325.3%
ROIC−53.5%
Return on equity−53.2%
Debt / equity0.17
Free cash flown/a
FCF marginn/a
Share count change+27.1%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | 0 | 8 | 63 |
| Operating income | −93 | −120 | −100 | −593 | −213 |
| Net income | −87 | −104 | −76 | −568 | −205 |
| Free cash flow | n/a | n/a | n/a | n/a | n/a |
Recent filings
- 4Insider transaction report
Aug 21, 2026 - 8-KResults of operations and financial condition
Aug 6, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 6, 2026 - 4Insider transaction report
Jul 17, 2026 - 8-KNew financial obligation
Jul 6, 2026 - 8-KEntry into a material agreement
Jun 30, 2026 - 8-KResults of a shareholder vote
May 27, 2026 - 8-KResults of operations and financial condition
May 4, 2026